A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intramuscularly Administered TMB-607 in HIV-Negative Volunteers
Latest Information Update: 13 May 2020
At a glance
- Drugs PPL 100 (Primary) ; PPL 100 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors TaiMed Biologics
- 08 May 2020 Status changed from suspended to discontinued.
- 09 Apr 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 09 Apr 2019 Status changed from recruiting to suspended.